



## Sosei Acquires Activus Pharma

Tokyo, Japan – 17 August 2010: Further to the announcement on 21 June 2010, Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), is pleased to announce the completion of acquisition of Activus Pharma Ltd. (“Activus”).

Activus, based in Chiba, Japan, specializes in nano-particle processing technology that keeps compounds virtually free from contamination and increases their solubility, and therefore enables the development of injections, ophthalmic solutions and inhalations with poorly soluble compounds where high purity is required.

The technology can be expected to generate new development candidates for Sosei, and partnership with other pharmaceutical companies will allow Sosei to realize revenue from this technology in a relatively short period of time.

### Enquiries:

Sosei Group Corporation	
Tokyo Office	London Office
Hidetoshi TORAMI Executive Officer and CFO	Yumi YAMAMOTO Vice President, IR and Finance
+81-(0)3-5210-3399	+44-(0)20-7691-2087
<a href="mailto:htorami@sosei.com">htorami@sosei.com</a>	<a href="mailto:yyamamoto@sosei.com">yyamamoto@sosei.com</a>

### Notes for Editors:

#### About Sosei

Sosei is an international biopharmaceutical company anchored in Japan with a global reach. It practises a reduced risk business model by acquiring compounds from, and bringing compounds into, Japan through exploitation of its unique position within global markets. For further information about Sosei, please visit [www.sosei.com](http://www.sosei.com).

#### Forward-Looking Statements

*This press release contains “forward-looking statements”, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei’s actual results to differ materially from those expressed or implied by the forward-looking statements, including adverse results in clinical development programmes; failure to obtain patent*

*protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*